(Q37556550)

21 August 2017

1 reference

title

Rivastigmine in Parkinson's disease dementia (English)

1 reference

21 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Shilpa Chitnis

1

1 reference

21 August 2017

Jayaraman Rao

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

8

1 reference

21 August 2017

page(s)

941-955

1 reference

The association of incident dementia with mortality in PD.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Clinicopathological analysis of dementia disorders in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

The effect of age of disease onset on neuropsychological performance in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Parkinson's disease: Clinical analysis of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cognitive deficits in the early stages of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Neuropsychological differences between the dementias of Alzheimer's and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Management of psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Clozapine-responsive tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Treatment of psychosis in Parkinson's disease: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Acetylcholine in mind: a neurotransmitter correlate of consciousness?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Functional characterization of intrinsic cholinergic interneurons in the cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Imaging amyloid deposition in Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Depletion of cholinergic neurons in the nucleus of the medial septum and the vertical limb of the diagonal band in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Distribution of m1 muscarinic acetylcholine receptors in the hippocampus of patients with Alzheimer's disease and dementia with Lewy bodies-an immunohistochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Nicotinic alpha4beta2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Rivastigmine exposure provided by a transdermal patch versus capsules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Benefits of rivastigmine on attention in dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Risk of dementia in Parkinson's disease: a community-based, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Changes in motor subtype and risk for incident dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

A review of rivastigmine: a reversible cholinesterase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Management of Parkinson's disease dementia : practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Cognitive dysfunction and dementia in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903105420

10.1517/17425250903105420

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference